ID | 1145 |
Name of the vaccine | Pneumosil |
Microbe | Bacteria |
Disease name | Pneumococcal |
Name of bacteria | Streptococcus pneumoniae |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | 6 weeks to 2 years |
Description of the vaccine | Pneumococcal polysaccharide conjugate Vaccine (10-valent) for serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F and 23F. |
Name of the manufacturer | By collaboration between Serum Institute of India Pvt Ltd and PATH. |
Name of the manufacturing country | India |
Year of manufacture | 2020 |
Clinical Phase status | Approved |
Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
Efficacy | NA |
Vaccine formulation | Sterile suspension as 0.5 and 2.5 mL vial. |
Dosage | Single 0.5 mL dose. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | Immunization against invasive disease, pneumonia and acute otitis media. |
Export | NA |
Approval | WHO prequalified |
Adjuvant | Aluminium phosphate |
Repurposing | For pneumococcal infections. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://pneumosil.com/vaccine/ |
Other name | NA |
Additional Links | NA
|